NCT01465035View on ClinicalTrials.gov

A Study to Determine the Safety and Immunogenicity of Co-administration of the Candidate Influenza Vaccine MVA-NP+M1 and Seasonal Influenza Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Influenza
Interventions
BIOLOGICAL

TIV and MVA-NP+M1

1.5 x 108 pfu MVA-NP+M1, intramuscular injection into the thigh. Inactivated Influenza Vaccine (Split Virion) 0.5ml (containing 15 micrograms of haemagglutinin, intramuscular injection into the thigh

BIOLOGICAL

Saline placebo and seasonal influenza vaccine TIV

Saline placebo, intramuscular injection into the thigh. Inactivated Influenza Vaccine (Split Virion) 0.5ml (containing 15 micrograms of haemagglutinin, intramuscular injection into the thigh

Trial Locations (1)

OX3 7LJ

Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford

All Listed Sponsors
lead

University of Oxford

OTHER

NCT01465035 - A Study to Determine the Safety and Immunogenicity of Co-administration of the Candidate Influenza Vaccine MVA-NP+M1 and Seasonal Influenza Vaccine | Biotech Hunter | Biotech Hunter